Table 2.
Molecular metastasis subtypes MetA‐C in relation to metastasis and primary tumor morphology. Continuous variables given as median (25th; 75th percentiles).
| MetA (n = 51) | MetB (n = 12) | MetC (n = 9) | |
|---|---|---|---|
| Bone metastases | |||
| AR score (0–12) | 8 (4;12) | 10 (6;12) | 9 (4;12) |
| (n = 49) | (n = 12) | (n = 8) | |
| PSA score (0–12) | 9 (6;12) | 2 (1;6)***a | 6 (1;9)*a |
| (n = 51) | (n = 12) | (n = 9) | |
| Ki67 (%) | 14 (9;20) | 33 (22; 45)***a | 12 (8;28)*b |
| (n = 50) | (n = 12) | (n = 9) | |
| Chromogranin‐A (%) | 0 (0;0.2) | 0.2 (0;1.6)P = 0.05 a | 0 (0;0) |
| (n = 45) | (n = 12) | (n = 9) | |
| Cellular atypia (moderate; high) | 34; 17 | 2; 10**a | 2; 7*a |
| Gland formation (yes; no) | 20; 31 | 0; 12**a | 4; 5*a |
| MetA associated (n = 36) | MetB associated (n = 8) | MetC associated (n = 8) | |
|---|---|---|---|
| Primary tumor | |||
| AR score (0–12) | 12 (12;12) | 12 (10;12) | 10.5 (8;12) |
| (n = 34) | (n = 8) | (n = 8) | |
| PSA score (0–12) | 9 (8;12) | 6 (4;8)**a | 7 (6;10.5) |
| (n = 32) | (n = 8) | (n = 8) | |
| Ki67 (%) | 9 (6.5;14) | 19 (15;26)**a | 17 (11;30)*a |
| (n = 35) | (n = 8) | (n = 8) | |
| AR tumor stroma score (% of stroma cells positive) | 22 (15;30) | 11 (4;17)*a | 17 (7;20) |
| (n = 34) | (n = 8) | (n = 8) | |
| Reactive stroma score (1; 2; 3) | 11; 11; 0 | 0; 2; 7***a | 0; 6; 1*a, *b |
Metastasis subtype, MetA‐C, as determined from PCA of whole genome expression profiles followed by unsupervised clustering (Fig. 1). *P < 0.05, **P < 0.01, ***P < 0.001, asignificantly different from MetA, bsignificantly different from MetB.